Key facts
- This page summarizes BioStar Ventures III, L.P.'s Form 4 filing for Autonomix Medical, Inc. (AMIX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Jun 2024, 20:23.
BioStar Ventures III, L.P. - 18 Jun 2024 Form 4 Insider Report for Autonomix Medical, Inc. (AMIX)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- AMIX
- Reported as of
- 18 Jun 2024
- Net transaction value
- +$30,464
- SEC form
- 4
- Accepted by SEC
- 20 Jun 2024, 20:23:25 UTC
- Prior SEC filing
- 01 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- BioStar Ventures III, L.P. By: BioStar Ventures III, L.L.C. Its: General Partner /s/ Louis Cannon, MD Name: Louis Cannon, MD Title: Founder, Senior Managing Director
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
BioStar Ventures III, L.P. filed Form 4 for Autonomix Medical, Inc. (AMIX) on 20 Jun 2024.
Change
- Previous filing in this sequence was filed on 01 Feb 2024.
- Current net transaction value: +$30,464.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AMIX
transaction
Derivative
Warrant to Purchase Common Stock
Purchase
- Transaction value
- $30,464
- Shares
- +1,088,000
- Change %
- Price
- $0.0280*
- Shares after
- 1,088,000
- Date
- 18 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,088,000
- Exercise price
- $0.001000
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The ability of the Reporting Person to exercise the warrants is subject to a beneficial ownership limitation initially set at 4.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of common stock issuable upon exercise of the warrants. This beneficial ownership limitation may be increased or decreased at the election of the holder, provided that the beneficial ownership limitation in no event exceeds 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise of the warrants and any increase shall not be effective until the 61st day after notice of adjustment is provided to the Issuer.